Skip to main content
Clinical Trials/NL-OMON53722
NL-OMON53722
Recruiting
Not Applicable

Role of the central brain clock in the pathophysiology of insulin resistance - Brain Clock and Insulin Resistance

Amsterdam UMC0 sites30 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
De perfusie/activiteit van de centrale hersenklok (SCN)
Sponsor
Amsterdam UMC
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • Group 1: obese people with normal insulin sensitivity
  • age 25\-65 years
  • fasting plasma insulin \<\=62 pmol/L
  • fasting plasma glucose \<5\.6 mmol/L
  • HOMA\-IR \<\= 4\.5
  • Group 2: obese people with insulin resistance
  • age 25\-65 years
  • fasting plasma insulin \>62 pmol/L
  • fasting plasma glucose \>\=5\.6 mmol/L
  • not fulfilling the ADA criteria for type 2 DM

Exclusion Criteria

  • An extreme chronotype (midpoint of sleep on free days (MSFsc) before 2:00 or
  • after 6:00\).
  • Active psychiatric disorder (including circadian rhythm sleep disorder) as
  • defined in DSM 5
  • Disorders of the central nervous system (Early\-onset dementia, stroke,
  • epilepsy, Parkinson\*s disease, brain tumour)
  • Severe visual impairment (WHO classification)
  • Shift workers
  • Crossing \> 2 time zones in the 3 months before the study
  • Patients with type 2 DM receiving insulin treatment or GLP\-1 agonists

Outcomes

Primary Outcomes

Not specified

Similar Trials